Q4 2024 Management View CEO Richard Pops highlighted 2024 as a transformative year focused on profitability and pipeline development, achieving over $1.5 billion in revenue and $450 million in EBITDA ...

Abbott Laboratories ABT faced industry-wide challenges that exerted pressure on its profit margins. Factors such as rising ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Vertiv is projecting another year of sales growth as the bustling data center market continues to provide it with strong pipeline activity.

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Elliott Investment Management confirms a more than $2.5B stake in Phillips 66 and will seek to streamline the company, most ...

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...